NASDAQ: PBYIPuma Biotechnology Inc Stock
$8.00+0.10 (+1.27%)
Updated Jul 10, 2026
PBYI Price
$8.00
Fair Value Price
$17.56
Market Cap
$407.20M
52 Week Low
$3.03
52 Week High
$8.44
P/E
16x
P/B
3.17x
P/S
1.43x
PEG
N/A
Dividend Yield
N/A
Revenue
$227.18M
Earnings
$24.38M
Gross Margin
74.5%
Operating Margin
15.08%
Profit Margin
10.7%
Debt to Equity
0.5
Operating Cash Flow
$54M
Beta
0.98
Next Earnings
Aug 6, 2026
Ex-Dividend
N/A
Next Dividend
N/A
PBYI Overview
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PBYI's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +17.17% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important PBYI news, forecast changes, insider trades & much more!
PBYI News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PBYI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PBYI ($8.00) is undervalued by 54.43% relative to our estimate of its Fair Value price of $17.56 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
PBYI ($8.00) is significantly undervalued by 54.43% relative to our estimate of its Fair Value price of $17.56 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
PBYI is forecast by analysts... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PBYI due diligence checks available for Premium users.
Valuation
PBYI fair value
Fair Value of PBYI stock based on Discounted Cash Flow (DCF)
Price
$8.00
Fair Value
$17.56
Undervalued by
54.43%
PBYI ($8.00) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PBYI ($8.00) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PBYI is forecast by analysts... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PBYI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
16x
Industry
17.05x
Market
12.99x
PBYI is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
PBYI is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
PBYI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.17x
Industry
5.52x
PBYI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PBYI's financial health
Profit margin
Revenue
$44.8M
Net Income
-$3.8M
Profit Margin
-8.4%
PBYI's Earnings (EBIT) of $34.26M... subscribe to Premium to read more.
Interest Coverage Financials
PBYI's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$192.7M
Liabilities
$64.3M
Debt to equity
0.5
PBYI's short-term assets ($142.26M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PBYI's short-term assets ($142.26M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PBYI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PBYI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$15.4M
Investing
$2.5M
Financing
-$11.3M
PBYI's operating cash flow ($53.61M)... subscribe to Premium to read more.
Debt Coverage Financials
PBYI vs Biotech Stocks
Puma Biotechnology Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.